Sosei Group Corp., of Tokyo, plans to develop an inhaled triple therapy called QVM149 for moderate to severe asthma uncontrolled by standard ICS/LABA medication. The product is a fixed dose, once daily combination of the long-acting beta2 agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium bromide and the inhaled corticosteroid mometasone fuorate. First regulatory filings are planned for 2018.